- PR Newswire•14 hours ago
Shire plc (LSE: SHP; NASDAQ: SHPG), the leading biotechnology company focused on serving individuals with rare diseases, is presenting an update on its safety database describing 40 years of real-world experience with the bypassing agent FEIBA [Anti-Inhibitor Coagulant Complex]. Shire also revealed new in vitro data showing the potential for excessive thrombin generation when combining an investigational procoagulant bispecific antibody and bypass therapy for breakthrough bleeds. Recently, concerns have emerged related to the use of an investigational non-factor product when combined with marketed bypassing agents for hemophilia patients with inhibitors.
- Investor's Business Daily•15 hours ago
Thanksgiving week saw Shire's Xiidra lose some ground to rival Allergan in the dry-eye market, RBC says.
SHPG : Summary for Shire plc - American Depositary - Yahoo Finance
Shire plc (SHPG)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||148.01 x 200|
|Ask||194.72 x 100|
|Day's Range||173.06 - 175.50|
|52 Week Range||147.60 - 210.33|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||267.28|
|Dividend & Yield||0.80 (0.46%)|
|1y Target Est||N/A|